Literature DB >> 8614318

Physical inactivity and glucose intolerance in the multiethnic island of Mauritius.

M A Pereira1, A M Kriska, M L Joswiak, G K Dowse, V R Collins, P Z Zimmet, H Gareeboo, P Chitson, F Hemraj, A Purran.   

Abstract

The island nation of Mauritius, located in the southwest Indian Ocean, has a high prevalence of non-insulin-dependent diabetes mellitus (NIDDM) among all of its ethnic groups (Hindu and Muslim Indians, African-origin Creoles, and Chinese). These high rates of NIDDM among groups of varying genetic background provide strong support for the importance of environmental components in the etiology of the disease. Research in Mauritius using a simple activity scale has suggested that physical inactivity may be one of these components. The current investigation further examined the association between glucose tolerance and physical activity in middle-aged nondiabetic residents of Mauritius using a more extensive physical activity questionnaire (the Modifiable Activity Questionnaire). Excluding individuals with NIDDM, a statistically significant (P < 0.05) inverse relationship between physical activity and 2-h post-load glucose concentration was found for both males (rho = -0.14) and females (rho = -0.11). Stratifying by ethnic group, similar inverse correlations were observed in Hindu, Creole, and Chinese males, and in Hindu females (P < 0.05), as well as weaker relationships in Muslim males and Creole females (P < 0.10). Total physical activity remained an independent predictor of 2-h post-load glucose concentration after controlling for body mass index, waist-hip ratio, age, and family history of NIDDM. These data are supportive of a potentially important role of physical activity in the prevention of NIDDM in middle-aged inhabitants of Mauritius.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8614318

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  8 in total

Review 1.  Accumulation of physical activity for health gains: what is the evidence?

Authors:  A E Hardman
Journal:  Br J Sports Med       Date:  1999-04       Impact factor: 13.800

2.  Decreased physical fitness in borderline glucose tolerance men.

Authors:  Y Higaki; N Shono; M Nishizumi
Journal:  Environ Health Prev Med       Date:  1998-01       Impact factor: 3.674

3.  Predicting physical activity energy expenditure using accelerometry in adults from sub-Sahara Africa.

Authors:  Felix K Assah; Ulf Ekelund; Soren Brage; Kirsten Corder; Antony Wright; Jean C Mbanya; Nicholas J Wareham
Journal:  Obesity (Silver Spring)       Date:  2009-02-26       Impact factor: 5.002

4.  Appropriateness of current thresholds for obesity-related measures among Aboriginal people.

Authors:  Scott A Lear; Karin H Humphries; Jiri J Frohlich; C Laird Birmingham
Journal:  CMAJ       Date:  2007-12-04       Impact factor: 8.262

5.  A Cross-Sectional Analysis of the Association between Physical Activity and Visceral Adipose Tissue Accumulation in a Multiethnic Cohort.

Authors:  Iris A Lesser; Ann C Yew; Dawn C Mackey; Scott A Lear
Journal:  J Obes       Date:  2012-09-20

6.  Free-living physical activity energy expenditure is strongly related to glucose intolerance in Cameroonian adults independently of obesity.

Authors:  Felix K Assah; Ulf Ekelund; Soren Brage; Jean Claude Mbanya; Nicholas J Wareham
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 19.112

7.  The association between "hypertriglyceridemic waist" and sub-clinical atherosclerosis in a multiethnic population: a cross-sectional study.

Authors:  Danijela Gasevic; Axel C Carlsson; Iris A Lesser; Gb John Mancini; Scott A Lear
Journal:  Lipids Health Dis       Date:  2014-02-23       Impact factor: 3.876

8.  Clinical usefulness of lipid ratios to identify men and women with metabolic syndrome: a cross-sectional study.

Authors:  Danijela Gasevic; Jiri Frohlich; Gb John Mancini; Scott A Lear
Journal:  Lipids Health Dis       Date:  2014-10-10       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.